Four Companies to Know in Hungary
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
HUMAN BioPlazma Kft. is part of Kedrion Biopharma, an international company specializing in the collection and fractionation of blood plasma to produce and distribute plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as hemophilia and immune system deficiencies.
Kedrion was established in Italy in 2001, but the roots of the companies from which it was born stretch back several decades in the production of blood and plasma derived products. A primarily family-owned business, it places a high value on the welfare of those who benefit from its products and also on the people and communities where it operates. HUMAN BioPlazma became part of Kedrion in 2008, but its own roots extend back to 1922 when its predecessor, the Phylaxia Vaccine Manufacturing company founded its Human Department in Budapest.
HUMAN BioPlazma collects plasma in its own plasma collection centers applying apheresis technology, and also receives plasma for further processing deriving from the excess amounts of whole blood donations, which are not required for transfusiology purposes as the partner of the Hungarian National Blood Transfusion Service.
We have been well-matched to join Kedrion, sharing its commitments and values of quality products, community values and a highly professional workforce.
Contact
H-2100 Gödöllő
Táncsics M. út 80
Hungary
Tel: +36 28 53 22 00
Fax: +36 28 53 22 01
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Dr. Zsuzsanna Fürst, President of the Ethics Committee for Clinical Pharmacology, elaborates on the role and activities of the ethics committee, shares her insights on structural framework of the application…
Dr Beata Sperlagh, Deputy Director of the Institute of Experimental Medicine (IEM), shares her insights on the institute’s involvement in research and with the private sector, the key strengths of…
Irisz Lippai-Nagy, CEO of AmCham Hungary, shares insights on the drivers contributing to economic growth in Hungary, recent policies and reforms, the role of the association, and policy recommendations to…
Oliver Strommer, newly appointed executive director of the British Chamber of Commerce in Hungary (BCCH), introduces the Chamber and its refocused aim of becoming a more dynamic player in business…
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in…
Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also…
Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase…
Hungary’s Minister of Finance Mihály Varga has repeatedly underlined the importance of the pharmaceutical industry to the country’s economy in recent weeks. With this strong governmental backing, pharma stands to…
Hungary has long been one of the leading countries in Central and Eastern Europe for clinical trials. However, a downward trend in the number of research projects being conducted in…
Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that…
See our Cookie Privacy Policy Here
